Maridebart cafraglutide (MariTide) has early human Phase 1 evidence and a larger controlled Phase 2 obesity trial showing substantial weight loss. Multiple Phase 3 programmes are now underway, but it remains investigational.
Still uncertain: Marketing approval, Phase 3 treatment results, long-term cardiovascular outcomes, rare-event safety and real-world effectiveness.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
A first-in-human Phase 1 study established early safety/PK/PD and exploratory weight-loss signals, followed by a larger randomized Phase 2 obesity trial showing substantial weight loss including in participants with type 2 diabetes.
Regulatory status
Investigational; Phase 3 chronic-weight-management and cardiovascular studies are underway. No marketing authorisation identified.
Main limitations
Marketing approval, long-term cardiovascular outcomes, rare-event safety or real-world effectiveness.
Safety
GI adverse effects were common; escalation reduced tolerability burden in Phase 2.
Evidence reviewed
2026-09-20
i
Published Phase 1 and randomized Phase 2 evidence show substantial weight-loss signals, and multiple MARITIME Phase 3 programmes are now underway. MariTide remains investigational.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Evidence rule: an outcome-specific evidence label is not a recommendation, a safety rating or an overall score for the compound.
Evidence synthesis
✓Substantial Phase 2 efficacy with monthly/less-frequent dosing concept.
✓Both weight and glycaemic signals are substantial.
✓Regimen design materially affects tolerability.
Important limitations
!Multiple dose/escalation arms make simplistic 'monthly dose' summaries misleading.
!Phase II and antibody-peptide conjugate formulation.
!Phase II sample and duration limit rare-event assessment.
Selected study & evidence records
Phase 1 AMG 133 (maridebart cafraglutide) single- and multiple-ascending-dose study in obesity
2024 · Phase 1 randomized, double-blind, placebo-controlled single- and multiple-ascending-dose study · n=110 enrolled in registry; 75 in published principal SAD/MAD cohorts
The publication reported acceptable safety/tolerability and dose-dependent weight loss; in multiple-ascending-dose cohorts, weight loss was maintained for up to 150 days after the last dose.
GI adverse effects were common; escalation reduced tolerability burden in Phase 2.
Gastrointestinal adverse events were common in Phase 2, with better tolerability when dose escalation and lower starting doses were used. Long-term rare-event safety remains under study.
Technical details
Mechanism / biologyCombines GLP-1 receptor agonism with GIP receptor antagonism in a long-acting antibody-peptide conjugate intended for monthly or less-frequent dosing.
Route / formulation boundaryMaridebart cafraglutide is a long-acting antibody-peptide conjugate, not a conventional peptide vial.
Identity / data-quality noteAvoid calling MariTide simply a peptide; it is an antibody-peptide conjugate.
Study / label regimen evidencePhase 2 dose-ranging verified. Phase 2 studied 140, 280 or 420 mg every 4 weeks and a 420 mg every-8-week arm, with different escalation schedules.
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
3outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
